SG11202111131VA - Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations - Google Patents
Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrationsInfo
- Publication number
- SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA
- Authority
- SG
- Singapore
- Prior art keywords
- amorphous solid
- plasma concentrations
- enhanced performance
- therapeutic plasma
- achieving therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832606P | 2019-04-11 | 2019-04-11 | |
| PCT/US2020/027677 WO2020210629A1 (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111131VA true SG11202111131VA (en) | 2021-11-29 |
Family
ID=70465560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111131VA SG11202111131VA (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3953355A1 (enExample) |
| JP (2) | JP2022526656A (enExample) |
| KR (1) | KR20210151183A (enExample) |
| CN (1) | CN113924300A (enExample) |
| AR (1) | AR118650A1 (enExample) |
| AU (1) | AU2020271103A1 (enExample) |
| BR (1) | BR112021020257A2 (enExample) |
| CA (1) | CA3132530A1 (enExample) |
| CL (1) | CL2021002627A1 (enExample) |
| CO (1) | CO2021015054A2 (enExample) |
| EA (1) | EA202192753A1 (enExample) |
| IL (1) | IL287103A (enExample) |
| MX (2) | MX2021012288A (enExample) |
| PE (1) | PE20212367A1 (enExample) |
| SG (1) | SG11202111131VA (enExample) |
| TW (1) | TW202104228A (enExample) |
| WO (1) | WO2020210629A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4304561A1 (en) | 2021-03-09 | 2024-01-17 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| KR20240060820A (ko) | 2021-09-17 | 2024-05-08 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안 |
| JP2025525915A (ja) | 2022-08-01 | 2025-08-07 | ブリストル－マイヤーズ スクイブ カンパニー | 虚血性脳卒中を処置又は予防するためのミルベクシアンの使用 |
| WO2024167899A1 (en) | 2023-02-06 | 2024-08-15 | Bristol-Myers Squibb Company | Milvexian pharmaceutical compositions |
| WO2025099743A1 (en) * | 2023-11-07 | 2025-05-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of milvexian and solid-state forms thereof |
| WO2025126240A1 (en) * | 2023-12-12 | 2025-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions and use thereof |
| WO2025220042A1 (en) * | 2024-04-18 | 2025-10-23 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising asundexian and use thereof |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0224249A1 (en) | 1985-11-27 | 1987-06-03 | Syntex (U.S.A.) Inc. | Amorphous benzimidazole derivatives |
| DE69837903T2 (de) * | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| WO2010102245A1 (en) | 2009-03-05 | 2010-09-10 | Upsher-Smith Laboratories, Inc. | Solid dispersion comprising resveratrol |
| SG10201908467RA (en) * | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (enExample) * | 2014-10-01 | 2018-10-20 |
-
2020
- 2020-04-10 CA CA3132530A patent/CA3132530A1/en active Pending
- 2020-04-10 EA EA202192753A patent/EA202192753A1/ru unknown
- 2020-04-10 TW TW109112257A patent/TW202104228A/zh unknown
- 2020-04-10 PE PE2021001691A patent/PE20212367A1/es unknown
- 2020-04-10 SG SG11202111131VA patent/SG11202111131VA/en unknown
- 2020-04-10 MX MX2021012288A patent/MX2021012288A/es unknown
- 2020-04-10 WO PCT/US2020/027677 patent/WO2020210629A1/en not_active Ceased
- 2020-04-10 BR BR112021020257A patent/BR112021020257A2/pt unknown
- 2020-04-10 JP JP2021559853A patent/JP2022526656A/ja not_active Withdrawn
- 2020-04-10 KR KR1020217036797A patent/KR20210151183A/ko active Pending
- 2020-04-10 CN CN202080041944.7A patent/CN113924300A/zh active Pending
- 2020-04-10 AU AU2020271103A patent/AU2020271103A1/en active Pending
- 2020-04-10 EP EP20722195.3A patent/EP3953355A1/en active Pending
- 2020-04-13 AR ARP200101025A patent/AR118650A1/es unknown
-
2021
- 2021-10-07 MX MX2025011559A patent/MX2025011559A/es unknown
- 2021-10-07 IL IL287103A patent/IL287103A/en unknown
- 2021-10-07 CL CL2021002627A patent/CL2021002627A1/es unknown
- 2021-11-08 CO CONC2021/0015054A patent/CO2021015054A2/es unknown
-
2025
- 2025-05-20 JP JP2025083936A patent/JP2025131625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR118650A1 (es) | 2021-10-20 |
| TW202104228A (zh) | 2021-02-01 |
| IL287103A (en) | 2021-12-01 |
| BR112021020257A2 (pt) | 2021-12-07 |
| JP2022526656A (ja) | 2022-05-25 |
| EA202192753A1 (ru) | 2022-01-11 |
| AU2020271103A1 (en) | 2021-12-02 |
| US20220144835A1 (en) | 2022-05-12 |
| CA3132530A1 (en) | 2020-10-15 |
| WO2020210629A1 (en) | 2020-10-15 |
| PE20212367A1 (es) | 2021-12-21 |
| CO2021015054A2 (es) | 2021-11-19 |
| MX2025011559A (es) | 2025-11-03 |
| CN113924300A (zh) | 2022-01-11 |
| EP3953355A1 (en) | 2022-02-16 |
| CL2021002627A1 (es) | 2022-05-06 |
| KR20210151183A (ko) | 2021-12-13 |
| MX2021012288A (es) | 2021-11-12 |
| JP2025131625A (ja) | 2025-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287103A (en) | Improved performance of amorphous solids and factor formulations to achieve therapeutic plasma concentrations | |
| EP4149460B8 (en) | Therapeutic solid dosage forms | |
| GB2587486B (en) | Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof | |
| IL323369A (en) | Topical formulations for the treatment of peripheral nervous system diseases | |
| PH12013501574A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| PH12013501591A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| IN2013MU01696A (enExample) | ||
| EP3860621A4 (en) | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | |
| EP4284272A4 (en) | COMPOSITIONS AND METHODS OF SUSTAINED TREATMENT OF PAIN | |
| IL291543A (en) | Medical preparations and their use | |
| IL277913A (en) | Preparations containing strontium and methylsulfonylmethane (MSM) and their uses in treatment methods | |
| IL289236A (en) | Preparations and methods for treating fungal infections | |
| EP3694517A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF FIBROSIS | |
| EP4138852A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN | |
| EP4164619A4 (en) | TREATMENT METHODS AND FORMULATIONS | |
| HK40068978A (en) | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations | |
| EP4017873A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | |
| EP3893847A4 (en) | STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMS | |
| EP4072549A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DIASTOLIC DYSFUNCTION | |
| EP3976115A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEMOCHROMATOSIS | |
| GB202101161D0 (en) | Formulations for the treatment of tendinopathies | |
| HK40112773A (zh) | 治疗制剂及其用途 | |
| HK40089059A (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| GB202001137D0 (en) | Formulations for the treatment of tendinopathies | |
| HK40065186A (en) | Therapeutic agents and methods of treatment |